Status:
COMPLETED
HLA and KIR Associations With Infectious Viral Agents in an HIV Cohort of Women (WIHS)
Lead Sponsor:
National Cancer Institute (NCI)
Conditions:
HIV
Eligibility:
FEMALE
Brief Summary
Since the beginning of the HIV/AIDS epidemic, the number of women infected with HIV has rapidly increased and is continuing to climb. The Women's Interagency HIV Study is being conducted in several ci...
Detailed Description
The aim of the study is to examine the role of HLA and killer immunolobulin-like receptors (KIR) in the natural history of HPV, HCV, and HBV in HIV-positive and HIV-negative women. The immune response...
Eligibility Criteria
Inclusion
- INCLUSION CRITERIA:
- DNA and relevant clinical data from properly consented WIHS subjects (maximum estimated at 3500) will be provided to our lab for genotyping and analysis.
- EXCLUSION CRITERIA:
- No available subjects will be excluded.
Exclusion
Key Trial Info
Start Date :
July 15 2002
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
August 18 2010
Estimated Enrollment :
3500 Patients enrolled
Trial Details
Trial ID
NCT00339430
Start Date
July 15 2002
End Date
August 18 2010
Last Update
July 2 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
National Cancer Institute (NCI), 9000 Rockville Pike
Bethesda, Maryland, United States, 20892